Hakutulokset - Christian Scheffold

  • Näytetään 1 - 15 yhteensä 15 tuloksesta
Tarkenna hakua
  1. 1
    A phase I trial of autologous cytokine-induced killer cells for the treatment of relapsed Hodgkin disease and non-Hodgkin lymphoma

    A phase I trial of autologous cytokine-induced killer cells for the treatment of relapsed Hodgkin disease and non-Hodgkin lymphoma Tekijä Thomas Leemhuis, Sandra Wells, Christian Scheffold, Matthias Edinger, Robert S. Negrin

    Julkaistu 2005
    Hae kokoteksti Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  2. 2
    Long-term follow-up of overall survival for cabozantinib versus everolimus in advanced renal cell carcinoma

    Long-term follow-up of overall survival for cabozantinib versus everolimus in advanced renal cell carcinoma Tekijä Robert J. Motzer, Bernard Escudier, Thomas Powles, Christian Scheffold, Toni K. Choueiri

    Julkaistu 2018
    Hae kokoteksti Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  3. 3
    Phase II randomised discontinuation trial of cabozantinib in patients with advanced solid tumours

    Phase II randomised discontinuation trial of cabozantinib in patients with advanced solid tumours Tekijä Patrick Schöffski, Michael S. Gordon, David C. Smith, Razelle Kurzrock, Adil Daud, Nicholas J. Vogelzang, Yihua Lee, Christian Scheffold, Geoffrey I. Shapiro

    Julkaistu 2017
    Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  4. 4
    Paracrine interactions of basic fibroblast growth factor and interleukin-6 in multiple myeloma

    Paracrine interactions of basic fibroblast growth factor and interleukin-6 in multiple myeloma Tekijä Guido Bisping, Regine Leo, Doris Wenning, Berno Dankbar, Teresa Padró, Martin Kropff, Christian Scheffold, M. Kröger, Rolf M. Mesters, Wolfgang E. Berdel, Joachim Kienast

    Julkaistu 2003
    Hae kokoteksti Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  5. 5
    Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245408 (XL147), an Oral Pan-Class I PI3K Inhibitor, in Patients with Advanced Solid Tumors

    Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245408 (XL147), an Oral Pan-Class I PI3K Inhibitor, in Patients with Advanced Solid Tumors Tekijä Geoffrey I. Shapiro, Jordi Rodón, Cynthia Bedell, Eunice L. Kwak, José Baselga, Irene Braña, Shuchi S. Pandya, Christian Scheffold, A. Douglas Laird, Linh T. Nguyen, Yi Xu, Coumaran Égile, Gerald M. Edelman

    Julkaistu 2013
    Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  6. 6
    Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update

    Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free surv... Tekijä Toni K. Choueiri, Colin Hessel, Susan Halabi, Ben L. Sanford, M. Dror Michaelson, Olwen Hahn, Meghara Walsh, Thomas Olencki, Joel Picus, Eric J. Small, Shaker R. Dakhil, Darren R. Feldman, Milan Mangeshkar, Christian Scheffold, Daniel J. George, Michael J. Morris

    Julkaistu 2018
    Hae kokoteksti Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  7. 7
    Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial

    Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised,... Tekijä Robert J. Motzer, Thomas Powles, Mauricio Burotto, Bernard Escudier, María T. Bourlon, Amishi Y. Shah, Cristina Suárez, Alketa Hamzaj, Camillo Porta, Christopher Hocking, Elizabeth R. Kessler, Howard Gurney, Yoshihiko Tomita, Jens Bedke, Joshua Zhang, Burçin Şimşek, Christian Scheffold, Andrea B. Apolo, Toni K. Choueiri

    Julkaistu 2022
    Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  8. 8
    Nivolumab Plus Cabozantinib With or Without Ipilimumab for Advanced Hepatocellular Carcinoma: Results From Cohort 6 of the CheckMate 040 Trial

    Nivolumab Plus Cabozantinib With or Without Ipilimumab for Advanced Hepatocellular Carcinoma: Results From Cohort 6 of the CheckMate 040 Trial Tekijä Thomas Yau, Vittorina Zagonel, Armando Santoro, Mirelis Acosta-Rivera, Su Pin Choo, Ana Matilla, Aiwu Ruth He, Antonio Cubillo Gracián, Anthony B. El-Khoueiry, Bruno Sangro, Tarek E. Eldawy, Jordi Bruix, Giovanni Luca Frassineti, Gina M. Vaccaro, Marina Tschaika, Christian Scheffold, Petra C. Koopmans, Jaclyn Neely, Fabio Piscaglia

    Julkaistu 2022
    Hae kokoteksti Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  9. 9
    Nivolumab plus cabozantinib versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended follow-up from the phase III randomised CheckMate 9ER trial

    Nivolumab plus cabozantinib versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended follow-up from the phase III randomised CheckMate 9ER trial Tekijä Thomas Powles, Mauricio Burotto, Bernard Escudier, Andrea B. Apolo, María T. Bourlon, Amishi Y. Shah, Cristina Suárez, Camillo Porta, Carlos H. Barrios, Martin Eduardo Richardet, Howard Gurney, Elizabeth R. Kessler, Yoshihiko Tomita, Jens Bedke, Saby George, Christian Scheffold, P. Wang, В. Э. Федоров, Robert J. Motzer, Toni K. Choueiri

    Julkaistu 2024
    Hae kokoteksti Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  10. 10
    Atezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell carcinoma after progression with previous immune checkpoint inhibitor treatment (CONTACT-03): a multicentre, randomised, open-label, phase 3 trial

    Atezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell carcinoma after progression with previous immune checkpoint inhibitor treatment (CONTACT... Tekijä Sumanta K. Pal, Laurence Albigès, Piotr Tomczak, Cristina Suárez, Martin H. Voss, Guillermo de Velasco, Jad Chahoud, Anastasia Mochalova, Giuseppe Procopio, Hakim Mahammedi, Friedemann Zengerling, Chan Kim, Takahiro Osawa, Martín Ángel, Suyasha Gupta, Omara Khan, Guillaume Bergthold, Bo Liu, Melania Kalaitzidou, Mahrukh Huseni, Christian Scheffold, Thomas Powles, Toni K. Choueiri

    Julkaistu 2023
    Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  11. 11
    Cabozantinib in Combination With Atezolizumab for Advanced Renal Cell Carcinoma: Results From the COSMIC-021 Study

    Cabozantinib in Combination With Atezolizumab for Advanced Renal Cell Carcinoma: Results From the COSMIC-021 Study Tekijä Sumanta K. Pal, Bradley A. McGregor, Cristina Suárez, Che‐Kai Tsao, William Kelly, Ulka N. Vaishampayan, Lance C. Pagliaro, Benjamin L. Maughan, Yohann Loriot, Daniel Castellano, Sandy Srinivas, Rana R. McKay, Robert Dreicer, Thomas E. Hutson, Sarita Dubey, Scott Werneke, Ashok Panneerselvam, Dominic Curran, Christian Scheffold, Toni K. Choueiri, Neeraj Agarwal

    Julkaistu 2021
    Hae kokoteksti Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  12. 12
    Cabozantinib in Chemotherapy-Pretreated Metastatic Castration-Resistant Prostate Cancer: Results of a Phase II Nonrandomized Expansion Study

    Cabozantinib in Chemotherapy-Pretreated Metastatic Castration-Resistant Prostate Cancer: Results of a Phase II Nonrandomized Expansion Study Tekijä Matthew R. Smith, Christopher J. Sweeney, Paul G. Corn, Dana E. Rathkopf, David C. Smith, Maha Hussain, Daniel J. George, Celestia S. Higano, Andrea Harzstark, Oliver Sartor, Nicholas J. Vogelzang, Michael S. Gordon, Johann S. de Bono, Naomi B. Haas, Christopher J. Logothetis, Aymen Elfiky, Christian Scheffold, A. Douglas Laird, Frauke Schimmöller, Ethan Basch, Howard I. Scher

    Julkaistu 2014
    Hae kokoteksti Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  13. 13
    Cabozantinib in Patients With Advanced Prostate Cancer: Results of a Phase II Randomized Discontinuation Trial

    Cabozantinib in Patients With Advanced Prostate Cancer: Results of a Phase II Randomized Discontinuation Trial Tekijä David C. Smith, Matthew R. Smith, Christopher J. Sweeney, Aymen Elfiky, Christopher J. Logothetis, Paul G. Corn, Nicholas J. Vogelzang, Eric J. Small, Andrea Harzstark, Michael S. Gordon, Ulka N. Vaishampayan, Naomi B. Haas, Alexander I. Spira, Primo N. Lara, Chia‐Chi Lin, Sandy Srinivas, Avishay Sella, Patrick Schöffski, Christian Scheffold, Aaron Weitzman, Maha Hussain

    Julkaistu 2012
    Hae kokoteksti Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  14. 14
    Quality of Life Outcomes for Cabozantinib Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma: METEOR Phase III Randomized Trial

    Quality of Life Outcomes for Cabozantinib Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma: METEOR Phase III Randomized Trial Tekijä David Cella, Bernard Escudier, Nizar M. Tannir, Thomas Powles, Frede Donskov, Katriina Peltola, Manuela Schmidinger, Daniel Y.C. Heng, Paul N. Mainwaring, Hans J. Hammers, Jae‐Lyun Lee, Bruce J. Roth, Florence Marteau, Paul Williams, John E. Baer, Milan Mangeshkar, Christian Scheffold, Thomas E. Hutson, Sumanta K. Pal, Robert J. Motzer, Toni K. Choueiri

    Julkaistu 2018
    Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  15. 15
    Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma

    Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma Tekijä Toni K. Choueiri, Bernard Escudier, Thomas Powles, Paul N. Mainwaring, Brian I. Rini, Frede Donskov, Hans J. Hammers, Thomas E. Hutson, Jae‐Lyun Lee, Katriina Peltola, Bruce J. Roth, Georg A. Bjarnason, Lajos Géczi, Bhumsuk Keam, Pablo Maroto, Daniel Y.C. Heng, Manuela Schmidinger, Philip W. Kantoff, Anne E. Borgman-Hagey, Colin Hessel, Christian Scheffold, Gisela Schwab, Nizar M. Tannir, Robert J. Motzer

    Julkaistu 2015
    Hae kokoteksti Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:

Työkalut: